Chapter 6. Thienopyridine Response Variability and Resistance

  1. Stephen D. Wiviott MD Assistant Professor Investigator
  1. Udaya S. Tantry PhD Laboratory Director,
  2. Thomas A. Suarez MD and
  3. Paul A. Gurbel

Published Online: 19 FEB 2009

DOI: 10.1002/9781444303339.ch6

Antiplatelet Therapy In Ischemic Heart Disease

Antiplatelet Therapy In Ischemic Heart Disease

How to Cite

Tantry, U. S., Suarez, T. A. and Gurbel, P. A. (2008) Thienopyridine Response Variability and Resistance, in Antiplatelet Therapy In Ischemic Heart Disease (ed S. D. Wiviott), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303339.ch6

Editor Information

  1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, TIMI Study Group, Boston, MA, USA

Author Information

  1. Sinai Center for Thrombosis Research, Sinai Hospital Baltimore, MD, USA

Publication History

  1. Published Online: 19 FEB 2009
  2. Published Print: 28 NOV 2008

Book Series:

  1. The AHA Clinical Series

Book Series Editors:

  1. Elliott Antman MD, FAHA

Series Editor Information

  1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, TIMI Study Group, Boston, MA, USA

ISBN Information

Print ISBN: 9781405176262

Online ISBN: 9781444303339

SEARCH

Keywords:

  • platelet activation and aggregation - central to atherothrombotic complications of CVD;
  • platelet activation and aggregation and multiple receptor signaling pathways;
  • light transmittance aggregometry (LTA);
  • laboratory evaluation of clopidogrel responsiveness;
  • clopidogrel resistance mechanism;
  • clinical relevance of clopidogrel non-responsiveness;
  • management of clopidogrel resistance;
  • second generation thienopyridine - clopidogrel use

Summary

This chapter contains sections titled:

  • Introduction

  • Mechanism of action

  • Clopidogrel resistance - definition

  • Laboratory evaluation of clopidogrel responsiveness

  • Effect of time of treatment and dose on platelet responsiveness to clopidogrel

  • Mechanism of clopidogrel resistance

  • Relation of clopidogrel non-responsiveness and high post-treatment platelet reactivity to adverse clinical events

  • Management of clopidogrel resistance

  • New P2Y12 receptor antagonists

  • Conclusion

  • References